William Blair Keeps Their Buy Rating on Krystal Biotech Inc (KRYS)

By Carrie Williams

In a report released today, Raju Prasad from William Blair maintained a Buy rating on Krystal Biotech Inc (KRYSResearch Report). The company’s shares opened today at $31.05.

Prasad said:

“We continue to view the anticipated second quarter clinical update of the GEM trial as a significant near-term catalyst for shares. As we have noted previously (see our note, We See Durable Wound Closure and 30%-40% COL7A1 Expression as after reviewing the published literature, we believe that achieving roughly 30%-40% of wild-type (normal) levels of collagen VII could be sufficient to restore skin integrity and prevent skin blistering. We also believe that the presence of anchoring fibrils should be viewed qualitatively only due to its lack of direct correlation with clinical results.”

According to TipRanks.com, Prasad is a 5-star analyst with an average return of 23.1% and a 67.4% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Allogene Therapeutics Inc.

Currently, the analyst consensus on Krystal Biotech Inc is a Strong Buy with an average price target of $43.38, representing a 39.7% upside. In a report released today, Cowen & Co. also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

The company has a one-year high of $36.89 and a one-year low of $9.90. Currently, Krystal Biotech Inc has an average volume of 86.62K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017 and is headquartered in Pittsburgh, PA.